Company webinar

Percheron Therapeutics (ASX:PER)

Watch our webinar with Percheron Therapeutics, featuring Managing Director and CEO Dr James Garner. A presentation followed by live Q&A with the audience.

Date
October 31, 2024
Time
Where
Online
Entry
Free
Dr James Garner
Dr James Garner
Managing Director and CEO, Percheron Therapeutics (ASX:PER)

About the company

Percheron Therapeutics Limited (ASX: PER) is a biotech company focused on developing impactful new medicines for orphan diseases. The company’s lead drug candidate, avicursen (ATL1102), is currently the subject of an international phase II clinical trial in Duchenne muscular dystrophy, a devastating genetic disease that leads to progressive muscle wasting. The trial is expected to read-out in December 2024. Ahead of the read-out, the company’s CEO, Dr James Garner, provides an update on the company’s progress to date and its strategy for taking the drug forward.

Key topics

  • Overview of Percheron and their current focus
  • Duchenne muscular dystrophy
  • Current treatment landscape for Duchenne muscular dystrophy
  • The company's competitive advantage in an increasingly competitive market
  • The market opportunity for rare diseases such Duchenne and its commercial prospects
  • Clinical trial read-out and what the regulatory pathway looks like
  • Strategy for commercialising avicursen
  • Company’s cash position and runway

Watch the recording

More webinars

All webinars →

Go beyond the presentation

Management tells one side of the story. Sharewise clients get independent research and Advisor access across ASX, US and global markets.

Explore our services →